Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Giant cell arteritis (GCA) and Takayasu arteritis (TA) are two forms of large-vessel vasculitis (LVV). While they share similar inflammatory targets in the aorta and its major branches, they are fundamentally distinguished by their age of onset, with GCA typically affecting individuals over 50 years and TA those under 60. Unlike small-vessel vasculitides, LVV does not cause glomerulonephritis and tubulointerstitial nephritis. However, LVV frequently involves renal artery and its branches resulting in kidney ischemia. The aim of our trial was to assess the prevalence of chronic kidney disease (CKD) and its risk factors in patients with LVV.
In this single center retrospective cohort study, we included consecutive adult (≥18 years old) patients with LVV (TA and GCA), diagnosed in accordance with the American College of Rheumatology classification criteria (1990 and/or 2022) and/or Chapel Hill Consensus Conference (2012) definition. Renal artery involvement was established on the basis of medical imaging (CT-angiography, MRI, PET/CT, and/or duplex ultrasound). Data on serum creatinine levels, estimated GFR (using CKD-EPI equation), spot urine protein, and other markers of CKD (structural abnormalities of the kidney, kidney pathology, if available) were obtained from electronic medical records.
We included 47 patients with GCA and 201 patients with TA who were followed for a median of three and five years, respectively (Table 1). Hypercholesterolemia and hypertension were identified in more than half of the patients with LVV, despite the young age of those with TA. By the end of the follow-up, 19 (40%) patients with GCA and 14 (7%) patients with TA had an eGFR of <60 mL/min/1.73 m2, and two patients with TA required kidney replacement therapy (Table 2). Eight (4%) patients with TA had elevated spot urine protein. In total 30 (64%) GCA patients and 46 (23%) TA patients had traditional markers of CKD (eGFR <60 and/or proteinuria and/or structural abnormalities of the kidney). The prevalence of renal artery involvement was 6% in GCA patients and 40% in TA patients; bilateral involvement was noted in 19% of the TA patient cohort. In the multivariate linear regression model only age was significantly associated with eGFR by the end of the follow-up in both in TA and GCA patients. Four patients with a rapid decline of eGFR and/or prominent rise in proteinuria underwent kidney biopsy, which revealed AA-amyloidosis, mesangial proliferative glomerulonephritis (in a patient with an overlap of TA and Crohn’s disease), secondary focal segmental glomerulosclerosis, and granulomatous tubulointerstitial nephritis.
There is a high prevalence of universal and specific risk factors for chronic kidney disease in patients with LVV. Close monitoring for markers of chronic kidney disease is essential in patients with LVV.
